Premium
THE CARDIOVASCULAR EFFECTS OF BROMOCRIPTINE IN PARKINSONISM
Author(s) -
GREENACRE J.K.,
TEYCHENNE P.F.,
PETRIE A.,
CALNE D.B.,
LEIGH P.N.,
REID J.L.
Publication year - 1976
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1976.tb04877.x
Subject(s) - bromocriptine , medicine , blood pressure , supine position , heart rate , anesthesia , agonist , dopamine agonist , dopaminergic , cardiology , dopamine receptor , endocrinology , dopamine , prolactin , receptor , hormone
1 The cardiovascular effects of bromocriptine, a dopamine receptor agonist, were investigated in twenty‐eight Parkinsonian patients. 2 Bromocriptine caused a significant impairment of postural compensation with a fall in systolic pressure and an absence of the rise in diastolic pressure after standing for 1 min when patients taking active drug were compared to the same patients on placebo. The hypotensive effect persisted for at least 6 weeks of treatment. There was also a significant reduction in supine heart rate. 3 One patient had marked falls in supine and erect blood pressure after a single oral dose of bromocriptine (2.5 mg) and a further patient developed paroxysmal atrial tachyarrhythmias. Both blood pressure and heart rate changes reversed spontaneously after stopping bromocriptine. 4 It is proposed that dopaminergic mechanisms either in the central nervous system or the periphery contribute to cardiovascular regulation in man.